Find Nonprofit and Small Business Grants

Advance Search

Only Available for Paid Subscribers
Clear Filters
Search Filters

Grants and In-Kind Support to USA, Canada, and UK Researchers to Encourage the Development of Drugs to Prevent, Treat, and Reverse Alzheimer's Disease

ADDF-Harrington Scholar Program


GrantWatch ID#

Funding Source
and Harrington Discovery Institute
Array ( [0] => American Samoa (USA); [1] => Guam (USA); [2] => Puerto Rico (USA); [3] => Virgin Islands (USA); [4] => Northern Mariana Islands (USA); )

Geographic Focus
USA Territories: American Samoa (USA);   Guam (USA);   Puerto Rico (USA);   Virgin Islands (USA);   Northern Mariana Islands (USA);
Canada:Alberta;   British Columbia;   Manitoba;   New Brunswick;   Newfoundland and Labrador;   Northwest Territories;   Nova Scotia;   Nunavut;   Ontario;   Prince Edward Island;   Quebec;   Saskatchewan;   Yukon;

Important Dates
LOI Date: 05/29/23
Deadline: 09/11/23 5:00 PM EDT Save

Grant Description
Grants and in-kind assistance and advice to USA, Canada, and UK faculty members at IHEs or research centers to promote the development of drugs to prevent, treat, reverse, or slow the development of Alzheimer's disease and related dementias. Applicants must submit a letter of intent prior to applying. The program places high priority on targets related to emerging therapeutic areas for dementia and is particularly seeking projects related to glymphatic clearance and neurovascular health.
The ADDF-Harrington Scholar Program is dedicated to advancing academic discoveries into medicines for Alzheimer’s disease and related dementias. This unique award provides funding and project support by a team of pharmaceutical industry experts through a collaboration with the Alzheimer’s Drug Discovery Foundation (ADDF) and Harrington Discovery Institute Center for Brain Health Medicines.

Discoveries Sought:
The ADDF-Harrington Scholar award selection committee seeks breakthrough discoveries that demonstrate innovation, creativity and potential for clinical impact, including:
  • Discoveries deemed to address unmet medical needs
  • Modulators of novel targets
  • Potential to be developed into a commercial program
  • Strong intellectual property (IP) or protection strategy
  • May be either a small molecule, biologic, or other therapeutic modality
  • Diagnostics or devices only acceptable as part of a therapeutic development project

Funding Priorities:

Drug Targets

The 2023 ADDF-Harrington Scholar RFP places high priority on targets related to emerging therapeutic areas for dementia, particularly:

  • Neurovascular health (including blood brain barrier function and integrity, cerebral hypoperfusion, nutrient supply to the brain, endothelial interaction with pericytes and astrocytes)
  • Glymphatic clearance (including aquaporin 4, clearance of interstitial solutes, sleep dynamics, perivascular space)
Other novel targets are encouraged. These include, but are not limited to:
  • Epigenetics
  • Proteostasis
  • Neuroprotection
  • Synaptic activity and neurotransmitters
  • Inflammation
  • Mitochondrial health
  • Antioxidant defense
  • Metabolic function and brain energy
  • Brain insulin resistance
  • ApoE
  • Postnatal neurogenesis
  • Other aging targets (e.g. senescent cells)

For additional information about Funding Priorities and Expectations, see the Full Grant Text RFP below.


Additional Eligibility Criteria
Eligibility Criteria:
- Academic investigators at accredited medical centers, research institutions, and universities in the United States, Canada and United Kingdom only are eligible to apply.
- Lead investigator must have an MD, a PhD, or equivalent.
- Team should possess intellectual property (IP) or have potential for novel IP that has not yet been licensed to a for-profit entity.
- Researchers working on drug development programs that are relevant to but not presently focused on the Alzheimer’s field are encouraged to apply.

A project must have only a single Principal Investigator (PI), who is responsible for project oversight and financial management. The PI may engage collaborators, core labs or commercial CROs to execute any portion of the project.

Past recipients of Harrington awards may submit new and distinct proposals, but may not seek additional support for previously funded projects.

This RFP does not support anti-amyloid approaches (e.g. Abeta vaccines, beta- or gamma-secretase inhibitors) or cholinesterase inhibitors. Any approaches targeting tau should be differentiated from those in clinical development.

This RFP does not support target discovery, assay development or high throughput screening campaign.

Unallowable Costs:
ADDF funding is not provided for indirect costs/overhead, capital equipment, equipment service contracts, publication costs, or travel (unless travel is pre-approved under special circumstances).

Pre-Application Information
Below is the timeline for the 2023 ADDF-Harrington program.
- Call Opens for Letters of Intent (LOI): April 3, 2023
- LOI Submission Deadline: May 29, 2023 at 5:00 pm EDT
- Full Application Deadline for those Invited: September 11, 2023
- Announce 2023 ADDF-Harrington Scholars: March 2024

The awards are provided as milestone-driven payments. Progress will be reviewed regularly by an oversight committee.

Applications and award budgets should be built around milestones. Milestones are key points in a project that represent reliable, quantifiable indicators/deliverables of progress and are used to make decisions on further funding.

Applicants may only submit one LOI per cycle and one invited full proposal per cycle, but a single academic institution may have multiple applicants apply for funding for different projects within a cycle. Biotechnology companies are limited to the submission of one LOI and one invited full proposal per cycle.

For Therapeutics RFPs, applicants are invited to resubmit proposals up to two times if they are able to address the reviewers' concerns. Resubmissions should include a point-by-point response to the review critiques.

Harrington Discovery Institute/ADDF-Harrington:

More Information:

How to Apply:

Application Instructions:

Funding Opportunities:

Number of Grants
Each year up to two ADDF-Harrington Scholars are chosen.

Estimated Size of Grant
The award includes:
- Two-year grant
- Funding up to $600,000
- Opportunity to qualify for investment funds
- Drug development expertise and project management support
- A personalized team of drug developers and project manager for each award recipient
- Expert business, commercialization and clinical development advice
- Regulatory assistance
- Intellectual property (IP) review and advice
- Assistance identifying and securing additional financial support based on project needs

Term of Contract
The funding period is for two years.

Contact Information
Online application portal:

For scientific inquiries, please contact:
Harrington Discovery Institute
Andrew A. Pieper, MD, PhD
Director, Center for Brain Health Medicines
Harrington Discovery Institute

Alzheimer’s Drug Discovery Foundation
Meriel Owen, PhD
Associate Director, Search and Evaluation

For application submission inquiries, please contact:
Grants and Contracts Team

57 West 57th Street, Suite 904
New York, NY 10019

Grant News
Live Chat Chat Now